1 citations,
March 2024 in “Life” Dermoscopy can help assess the severity of chronic radiation-induced skin damage in head and neck cancer patients.
January 2024 in “Journal of Cosmetic Dermatology” Platelet-rich plasma may improve hair density and count in male pattern hair loss, but more high-quality research is needed.
May 2023 in “Frontiers in Endocrinology” Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
January 2023 in “Annals of dermatology/Annals of Dermatology” A substance called miR-1246 may help treat severe hair loss by reducing certain immune cell activities.
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.
87 citations,
December 2015 in “Cochrane library” No single treatment is clearly effective for central serous chorioretinopathy.
74 citations,
February 2011 in “Headache The Journal of Head and Face Pain” Sumatriptan injections, high-flow oxygen, and verapamil effectively treat cluster headaches.
19 citations,
November 2021 in “Reviews in endocrine and metabolic disorders” Sex hormones like estrogen and testosterone may affect COVID-19 severity differently in men and women, potentially influencing prevention and treatment strategies.
9 citations,
November 2021 in “Infectious Agents and Cancer” Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.